EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Ramaprasad Srinivasan, Sandeep Gurram iD, Eric A Singer, Abhinav Sidana, Munjid Al Harthy, Mark W Ball, Julia C Friend, Lisa Mac, Erin Purcell, Cathy D Vocke iD, Christopher J Ricketts, Heidi H Kong und 5 weitere

New England Journal of Medicine · 19.06.2025 · 392 (23) · 2346-2356

DOI: 10.1056/nejmoa2200900 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 19.06.2025. Verfasst von Ramaprasad Srinivasan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Renal Cell, Erlotinib Hydrochloride. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papillary renal-cell carcinoma. No effective therapy is known for patients with advanced HLRCC-associated papillary renal-cell carcinoma, and most patients die from progressive disease. METHODS: In this open-label, phase 2 study, we evaluated the efficacy of bevacizumab (10 mg per kilogram of body weight every 2 weeks) and erlotinib (150 mg once daily) in patients with advanced HLRCC-associated or sporadic papillary renal-cell carcinoma. The primary end point was overall response; secondary end points included progression-free and overall survival. RESULTS: A total of 43 patients with HLRCC-associated papillary renal-cell carcinoma and 40 patients with sporadic papillary renal-cell carcinoma were enrolled. A confirmed response occurred in 31 patients (72%; 95% confidence interval [CI], 57 to 83) with HLRCC-associated papillary renal-cell carcinoma; the median progression-free survival was 21.1 months (95% CI, 15.6 to 26.6), and the median overall survival was 44.6 months (95% CI, 32.7 to could not be estimated). A confirmed response occurred in 14 patients (35%; 95% CI, 22 to 51) with sporadic papillary renal-cell carcinoma, with a median progression-free survival of 8.9 months (95% CI, 5.5 to 18.3) and a median overall survival of 18.2 months (95% CI, 12.6 to 29.3). The most common treatment-related adverse events were acneiform rash (93%), diarrhea (89%), and proteinuria (78%). The most common treatment-related adverse events of grade 3 or higher were hypertension (34%) and proteinuria (17%). CONCLUSIONS: The combination of bevacizumab and erlotinib showed antitumor activity in patients with HLRCC-associated or sporadic papillary renal-cell carcinoma. Toxic effects were those known to be associated with this combination. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01130519.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Renal CellErlotinib HydrochlorideKidney NeoplasmsLeiomyomatosisNeoplastic Syndromes, HereditaryAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalResponse Evaluation Criteria in Solid TumorsKaplan-Meier EstimateTreatment OutcomeAdministration, OralInfusions, IntravenousSkin NeoplasmsUterine Neoplasms

Substanzen

BevacizumabErlotinib Hydrochloride

Autor:innen und Institutionen

  • Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.
  • Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.
  • Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD.
  • Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Frederick, MD.
  • Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

ORCID-Profile: Sandeep Gurram, Cathy D Vocke

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Srinivasan, R., Gurram, S., Singer, E. A., Sidana, A., Al Harthy, M., Ball, M. W., Friend, J. C., Mac, L., Purcell, E., Vocke, C. D., Ricketts, C. J., Kong, H. H., Cowen, E. W., Malayeri, A. A., Shih, J. H., Merino, M. J., & Linehan, W. M. (2025). Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. New England Journal of Medicine, 392(23), 2346-2356. https://doi.org/10.1056/nejmoa2200900

Vancouver

Srinivasan R, Gurram S, Singer EA, Sidana A, Al Harthy M, Ball MW, et al. Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. New England Journal of Medicine. 2025;392(23):2346-2356. doi:10.1056/nejmoa2200900

BibTeX
@article{Srinivasan2025,
  author = {Srinivasan, Ramaprasad and Gurram, Sandeep and Singer, Eric A and Sidana, Abhinav and Al Harthy, Munjid and Ball, Mark W and Friend, Julia C and Mac, Lisa and Purcell, Erin and Vocke, Cathy D and Ricketts, Christopher J and Kong, Heidi H and Cowen, Edward W and Malayeri, Ashkan A and Shih, Joanna H and Merino, Maria J and Linehan, W Marston},
  title = {Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {23},
  pages = {2346--2356},
  doi = {10.1056/nejmoa2200900}
}
Kostenlos starten →